Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation

Xin-guang Liu; Yu Liu; Feng Chen

doi:10.18632/oncotarget.12533

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation

Xin-guang Liu, Yu Liu and Feng Chen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:3711-3723. https://doi.org/10.18632/oncotarget.12533

Metrics: PDF 3246 views | HTML 4470 views | ?

Abstract

Xin-guang Liu1,*, Yu Liu2,* and Feng Chen1,3

1 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China

2 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China

3 Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing, China

* These authors have contributed equally to this paper

Correspondence to:

Feng Chen, email:

Keywords: soluble fibrinogen-like protein 2; immunoregulation; transplantation; hepatitis; autoimmunity

Received: July 25, 2016 Accepted: September 29, 2016 Published: October 08, 2016

Abstract

Soluble fibrinogen-like protein 2 (sFGL2) is the soluble form of fibrinogen-like protein 2 belonging to the fibrinogen-related protein superfamily. It is now well characterized that sFGL2 is mainly secreted by regulatory T cell (Treg) populations, and exerts potently immunosuppressive activities. By repressing not only the differentiation and proliferation of T cells but also the maturation of dendritic cells (DCs), sFGL2 acts largely as an immunosuppressant. Moreover, sFGL2 also induces apoptosis of B cells, tubular epithelial cells (TECs), sinusoidal endothelial cells (SECs), and hepatocytes. This mini-review focuses primarily on the recent literature with respect to the signaling mechanism of sFGL2 in immunomodulation, and discusses the clinical implications of sFGL2 in transplantation, hepatitis, autoimmunity, and tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12533

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation

Abstract